TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3020983

Group type: EXPERIMENTAL
Intervention: Today contraceptive sponge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diaphragm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Today contraceptive sponge (nulliparous women)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diaphragm (nulliparous women)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Today contraceptive sponge (parous women)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diaphragm (parous women)
Number of subjects: 0
Study: 29928603

Group type: EXPERIMENTAL
Intervention: L4‐5 and L5‐S1 transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 217

Group type: COMPARATOR
Intervention: L4‐5 TLIF
Number of subjects: 217
Study: 27247914

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg oral 90 minutes before surgery
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lidocaine 1.5 mg/kg intravenous 90 seconds before intubation
Number of subjects: 86
Study: 24982492

Group type: EXPERIMENTAL
Intervention: Telehealth care delivery by front-line health professionals
Number of subjects: 32
Study: 23715582

Group type: EXPERIMENTAL
Intervention: Ridaforolimus 40 mg once per day for 5 days every week
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Number of subjects: 711
Study: 20884464

Group type: EXPERIMENTAL
Intervention: Three prunes (11.43g) soaked in water, consumed daily for 8 weeks
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Six prunes (23g) soaked in water, consumed daily for 8 weeks
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group given a glass of water daily for 8 weeks
Number of subjects: 166
Study: 18447225

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation combined with target-controlled infusion (TCI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Target-controlled infusion (TCI)
Number of subjects: 60
Study: 16390570

Group type: COMPARATOR
Intervention: Proseal laryngeal mask airway (PLMA)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Modified Airway Management Device (AMD)
Number of subjects: 82
Study: 14661563

Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen 50 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Suppository indomethacin 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 11340886

Group type: EXPERIMENTAL
Intervention: 7.5% sodium bicarbonate buffered lidocaine (pH 7.2)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:200,000 epinephrine and 1 ml of 7.5% sodium bicarbonate
Number of subjects: 232

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:200,000 epinephrine and 450 units of hyaluronidase (15 U/ml)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 232
Study: 8772331

Group type: EXPERIMENTAL
Intervention: 4 mg of oral salbutamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1602191

Group type: EXPERIMENTAL
Intervention: Vaccine group (MDT + 8 intradermal injections of M. w. every 3 months)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (MDT + starch injections as placebo)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Vaccine group
Number of subjects: 87
Study: 6218755

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 48
Study: 30809967

Group type: EXPERIMENTAL
Intervention: Chiglitazar (CHI) 48 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride (MET) 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of CHI and MET
Number of subjects: 0
Study: 30303516

Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept and high-dose interleukin 2 (arm A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: High-dose interleukin 2 alone (arm B)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Overall survival for arm A
Number of subjects: 89

Group type: COMPARATOR
Intervention: Overall survival for arm B
Number of subjects: 89
Study: 27650287

Group type: EXPERIMENTAL
Intervention: High-MUFA diet (n=18) for 8 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-MUFA diet (n=16)
Number of subjects: 38

Group type: COMPARATOR
Intervention: High-carbohydrate/high-fibre/low-glycaemic index diet (CHO/fibre diet, n=17)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-MUFA diet (n=18)
Number of subjects: 38
Study: 24384945

Group type: EXPERIMENTAL
Intervention: Posterior-cruciate-ligament-stabilized (PS) technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Posterior-cruciate-ligament-retaining (PCR) technique
Number of subjects: 100
Study: 22705426

Group type: EXPERIMENTAL
Intervention: Daily distribution of RUF-Nias biscuits
Number of subjects: 99

Group type: COMPARATOR
Intervention: Weekly distribution of RUF-Nias biscuits
Number of subjects: 99
Study: 20153570

Group type: EXPERIMENTAL
Intervention: Ghrelin levels in malnourished tuberculosis group
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ghrelin levels in well-nourished tuberculosis group
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Malnutrition score correlation with ghrelin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: TNF-alpha and IL-6 levels in malnourished tuberculosis group
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Plasma levels of ghrelin
Number of subjects: 23
Study: 18999067

Group type: EXPERIMENTAL
Intervention: Automated information extraction techniques
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Two-stage architecture combining a text classifier with a weak regular expression matcher
Number of subjects: 88
Study: 15830967

Group type: EXPERIMENTAL
Intervention: End range passive flexion movements (2 series of 10 repetitions)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: End range passive extension movements (2 series of 10 repetitions)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 55
Study: 11954880

Group type: EXPERIMENTAL
Intervention: Aspirin (up to 3g daily)
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Paracetamol (up to 3g daily)
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Ibuprofen (up to 1.2g daily)
Number of subjects: 4291
Study: 10980841

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 70000

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 70000

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 70000
Study: 7751888

Group type: EXPERIMENTAL
Intervention: Thoracic XRT with cisplatin 70 mg/m2 every 3 weeks for three cycles
Number of subjects: 240

Group type: COMPARATOR
Intervention: Thoracic XRT alone, 60 to 65 Gy total tumor dose in daily fractions of 1.80 to 2.00 Gy
Number of subjects: 240
Study: 2113611

Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg) daily on days 4 through 17
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg) (groups 3 and 4 combined)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg) (in subgroup with lowest spinal bone mineral density)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Phosphate (1.0 g) twice daily on days 1 through 3
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 1104247

Group type: EXPERIMENTAL
Intervention: Proteolytic enzyme mouthwash consisting mainly of neutral and alkaline proteases and amylase
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Proteolytic enzyme mouthwash
Number of subjects: 131
Study: 31973645

Group type: EXPERIMENTAL
Intervention: Palliative care services provided by a multiprofessional team in the hospital, villages, and homes; short-acting morphine oral solution as the only available strong opioid.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Palliative care services in rural settings with advanced planning and budgeting.
Number of subjects: 101
Study: 31083190

Group type: EXPERIMENTAL
Intervention: Neuroendoscopic treatment guided by body surface projection
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 69
Study: 28112771

Group type: EXPERIMENTAL
Intervention: Katz‐ADL index score
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: Lawton IADL scale
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: Minimum Detectable Change (MDC)
Number of subjects: 3184
Study: 25988553

Group type: EXPERIMENTAL
Intervention: Fish oil-enriched dairy drink (400 mL/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control dairy drink (400 mL/day)
Number of subjects: 110
Study: 24156205

Group type: EXPERIMENTAL
Intervention: Colgate Sensitive toothpaste (5% potassium nitrate and 1,000 ppm fluoride)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Colgate Cibaca toothpaste (1,000 ppm fluoride; Negative control)
Number of subjects: 100
Study: 21700966

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition supplemented with ω‐3 and ω‐6 fatty acids (Omegaven, 0.2 g/kg/d; Lipovenoes 10%, 0.6 g/kg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Parenteral nutrition with ω‐6 fatty acid (Lipovenoes 10%, 0.8 g/kg/d)
Number of subjects: 26
Study: 19371322

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1500 mg tomopenem
Number of subjects: 42
Study: 16513616

Group type: EXPERIMENTAL
Intervention: Single-phase whole-body CT scan (90 mL at 1.8 mL/min; delay, 90 s) during normal expiration (protocol B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single-phase whole-body CT scan (90 mL at 1.8 mL/min; delay, 90 s) during shallow breathing (protocol A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Multiphase CT scans during shallow breathing (protocol C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Multiphase CT scans during normal expiration (protocol D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single-phase whole-body CT scan during normal expiration (protocol B) and multiphase CT scan during normal expiration (protocol D)
Number of subjects: 60
Study: 12620440

Group type: COMPARATOR
Intervention: Rosiglitazone 4 mg b.i.d. with placebo (Group I)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg b.i.d. with clomiphene citrate (Group II)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Rosiglitazone (Group I)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rosiglitazone with clomiphene citrate (Group II)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Rosiglitazone (overall effect)
Number of subjects: 25
Study: 10854639

Group type: EXPERIMENTAL
Intervention: Venlafaxine monotherapy (225 mg, once or twice daily for 6 weeks)
Number of subjects: 15
Study: 9093725

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus best supportive care
Number of subjects: 61

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 61
Study: 8097400

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 75 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 27
Study: 3548684

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 30211989

Group type: EXPERIMENTAL
Intervention: Test dental gel containing 2.6% edathamil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control gel
Number of subjects: 10
Study: 27050038

Group type: EXPERIMENTAL
Intervention: Chiropractic care for 12 weeks
Number of subjects: 60
Study: 24912461

Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cognitive Defusion (CD)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control intervention focusing on participants' negative thoughts
Number of subjects: 142
Study: 22145709

Group type: EXPERIMENTAL
Intervention: Free-standing HEPA filter placed in the child's sleeping area
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Free-standing HEPA filter and window-mounted AC
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study: 19725842

Group type: EXPERIMENTAL
Intervention: Type I BAV
Number of subjects: 89

Group type: COMPARATOR
Intervention: Type II BAV
Number of subjects: 89
Study: 18414647

Group type: EXPERIMENTAL
Intervention: 400 mg albendazole administered every 6 months for 2 years (5 rounds)
Number of subjects: 3935

Group type: EXPERIMENTAL
Intervention: Vitamin A administered every 6 months
Number of subjects: 3935

Group type: COMPARATOR
Intervention: Control group (no albendazole treatment)
Number of subjects: 3935
Study: 16012502

Group type: EXPERIMENTAL
Intervention: Bioabsorbable tacks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Transosseous sutures
Number of subjects: 8
Study: 11868059

Group type: EXPERIMENTAL
Intervention: Niacin 50 mg administered by mouth 2 times daily for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9878944

Group type: EXPERIMENTAL
Intervention: Tasosartan 50 mg, increased to 100 mg and then to 200 mg if SiDBP > 90 mm Hg
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 7495780

Group type: EXPERIMENTAL
Intervention: Interferon-alfa therapy (3 MU every day for 3 months)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Interferon-alfa therapy (3 MU every other day for 3 months)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Interferon-alfa therapy (3 MU every other day for 6 months)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Interferon-alfa therapy
Number of subjects: 25
Study: 1902264

Group type: EXPERIMENTAL
Intervention: Continuous epidural (ED) fentanyl
Number of subjects: 32

Group type: COMPARATOR
Intervention: Continuous intravenous (IV) fentanyl
Number of subjects: 32
Study: 7325630

Group type: EXPERIMENTAL
Intervention: Amoxicillin 250 mg twice daily for 4 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ampicillin 250 mg twice daily for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both Amoxicillin and Ampicillin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Amoxicillin and Ampicillin
Number of subjects: 26
Study: 30964385

Group type: EXPERIMENTAL
Intervention: ACP video
Number of subjects: 92

Group type: COMPARATOR
Intervention: Informational video about the hospital's surgical program
Number of subjects: 92
Study: 28556876

Group type: EXPERIMENTAL
Intervention: CogniPlus (computer-based cognitive training)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Classical group-based cognitive training
Number of subjects: 60
Study: 25998198

Group type: COMPARATOR
Intervention: Conventional haemodialysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Online haemodiafiltration
Number of subjects: 20
Study: 23906374

Group type: EXPERIMENTAL
Intervention: Empagliflozin 1, 5, 10, 25, or 50 mg QD
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 to 50 mg QD
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 495
Study: 21817188

Group type: EXPERIMENTAL
Intervention: Drug conservation (DC; interrupt ART until CD4(+) T-cell count <250)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Viral suppression (VS; continued use of ART)
Number of subjects: 675
Study: 19655439

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy (complete response)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Nodal-negative carcinomas
Number of subjects: 125
Study: 15780528

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen replacement therapy (TERT) - 100 microg 17beta‐estradiol (Climara forte TTS) once a week for 3 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 11900782

Group type: EXPERIMENTAL
Intervention: Alcohol (target peak BAC of 0.05 g/dl)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo-alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Soda (diet Sprite)
Number of subjects: 20
Study: 10527965

Group type: EXPERIMENTAL
Intervention: 150 IU recombinant follicle stimulating hormone (recFSH, Puregon)
Number of subjects: 165

Group type: COMPARATOR
Intervention: 225 IU highly purified urinary follicle stimulating hormone (uFSH-HP, Metrodin-HP)
Number of subjects: 165
Study: 7859944

Group type: EXPERIMENTAL
Intervention: Insulin concentration increased to 416 +/- 22 pmol/l (step I), 1,170 +/- 79 pmol/l (step II), and 15,936 +/- 1,126 pmol/l (step III) in control subjects; LBF increased from 287 +/- 23 ml.min-1.leg-1 (basal) to 308 +/- 31 ml.min-1.leg-1 (I), 371 +/- 29 ml.min-1.leg-1 (II), and 434 +/- 32 ml.min-1.leg-1 (III).
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Insulin concentration increased to 509 +/- 43 pmol/l (step I), 1,299 +/- 122 pmol/l (step II), and 16,524 +/- 1,916 pmol/l (step III) in NIDDM subjects; LBF increased from 302 +/- 12 ml.min-1.leg-1 (basal) to 362 +/- 9 ml.min-1.leg-1 (I), 409 +/- 17 ml.min-1.leg-1 (II), and 472 +/- 29 ml.min-1.leg-1 (III).
Number of subjects: 15
Study: 1954811

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both CSII and CIT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 25
Study: 6781390

Group type: COMPARATOR
Intervention: Antimicrobial prophylaxis ($85.82 per year)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis
Number of subjects: 0
Study: 31525702

Group type: EXPERIMENTAL
Intervention: Individually tailored dietary intervention over a 6‐mo period
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard care for 6 mo followed by individually tailored dietary intervention for the next 6 mo
Number of subjects: 39
Study: 30462259

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FCH)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 28411254

Group type: EXPERIMENTAL
Intervention: romiplostim
Number of subjects: 1111

Group type: COMPARATOR
Intervention: control (placebo or standard of care)
Number of subjects: 1111
Study: 26494159

Group type: EXPERIMENTAL
Intervention: WhatsApp
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control
Number of subjects: 136
Study: 24494279

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with herbal acupoint sticking (group A)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Electroacupuncture alone (group B)
Number of subjects: 102
Study: 21555816

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) 200 mg twice daily or 400 mg once daily
Number of subjects: 569

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATZ/r)
Number of subjects: 569
Study: 19736634

Group type: EXPERIMENTAL
Intervention: Sharp dissection with meticulous ligation of lymphatic tissue
Number of subjects: 154

Group type: COMPARATOR
Intervention: Electrocoagulation technique
Number of subjects: 154
Study: 17113564

Group type: EXPERIMENTAL
Intervention: Prone posture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Stoop posture
Number of subjects: 15
Study: 15686176

Group type: EXPERIMENTAL
Intervention: Paramedian suboccipital mini-craniectomy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Large suboccipital craniectomy
Number of subjects: 46
Study: 12596616

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg (group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg/kg and Atracurium 0.25 mg/kg (group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rocuronium 0.1 mg/kg to prime Atracurium 0.42 mg/kg (priming group)
Number of subjects: 120
Study: 9640195

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8583482

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Lisinopril 20 mg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 135
Study: 2698570

Group type: EXPERIMENTAL
Intervention: Gallopamil (3 X 60 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diltiazem (3 X 50 mg/day)
Number of subjects: 30
Study: 782510

Group type: EXPERIMENTAL
Intervention: Vicryl (8-0 monofilament)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Monofilament nylon or virgin silk (control)
Number of subjects: 45
Study: 31117957

Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD) group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Late-stage PD (LPD) patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy volunteers (HV) group
Number of subjects: 33
Study: 29103741

Group type: EXPERIMENTAL
Intervention: Home-based program (HBP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient physical therapy (OPT)
Number of subjects: 0
Study: 25266246

Group type: EXPERIMENTAL
Intervention: 5 cups per day of black tea
Number of subjects: 57

Group type: COMPARATOR
Intervention: Tea-like placebo (flavonoid-free caffeinated placebo)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Tea-like placebo
Number of subjects: 57
Study: 23241739

Group type: EXPERIMENTAL
Intervention: Palifermin (60 μg/kg/day) i.v. for 3 consecutive days before high-dose Melphalan (HDM)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Palifermin (60 μg/kg/day) i.v. for 3 consecutive days before and after HDM
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 21525181

Group type: EXPERIMENTAL
Intervention: Brachial plexus blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-blocked upper extremity
Number of subjects: 0
Study: 18373046

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 267

Group type: COMPARATOR
Intervention: TVT-O
Number of subjects: 267
Study: 16110353

Group type: EXPERIMENTAL
Intervention: Astaxanthin 16 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12520750

Group type: EXPERIMENTAL
Intervention: Intraartery chemotherapy with Taxol 135 mg/m2 and DDP 80 mg/m2
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intravenous chemotherapy with Taxol 135 mg/m2 and DDP 80 mg/m2
Number of subjects: 57